A5057238532- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cardiac Valve Diseases and Treatments
- Parathyroid Disorders and Treatments
- Cardiac Structural Anomalies and Repair
- Cardiovascular Function and Risk Factors
- Mechanical Circulatory Support Devices
- Cardiomyopathy and Myosin Studies
- Cardiac Arrest and Resuscitation
- Diabetes Treatment and Management
- Cardiac Imaging and Diagnostics
- Eosinophilic Disorders and Syndromes
- Tissue Engineering and Regenerative Medicine
- Neuroendocrine Tumor Research Advances
- Electrospun Nanofibers in Biomedical Applications
- Infective Endocarditis Diagnosis and Management
- Cardiac electrophysiology and arrhythmias
- Metabolism, Diabetes, and Cancer
- Atrial Fibrillation Management and Outcomes
- Chemotherapy-induced cardiotoxicity and mitigation
- Sarcoidosis and Beryllium Toxicity Research
- Medical Imaging and Pathology Studies
- Heart Failure Treatment and Management
- Coronary Interventions and Diagnostics
- Angiogenesis and VEGF in Cancer
- Eosinophilic Esophagitis
University Hospital of Bern
2018-2024
University of Bern
2019-2024
Wilhelminen Hospital
2023-2024
Case Western Reserve University
2023
Medical University of Vienna
2018
Innsbruck Medical University
2015
Harvard Stem Cell Institute
2012-2014
Brigham and Women's Hospital
2012-2014
Harvard University
2012-2014
University of Cape Town
2008-2014
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve clinical outcomes in heart failure patients with reduced and preserved left ventricular ejection fraction (LVEF), but have not yet been investigated transthyretin amyloid cardiomyopathy (ATTR-CM). This study aimed to evaluate tolerability, outcomes, changes NT-proBNP levels glomerular filtration rate (GFR) ATTR-CM treated dapagliflozin.
Background The prevalence of calcific aortic stenosis and amyloid transthyretin cardiomyopathy (ATTR-CM) increase with age, they often coexist. objective was to determine the ATTR-CM in patients severe evaluate differences presentations outcomes concomitant undergoing transcatheter valve implantation. Methods Results Prospective screening for Technetium99-3,3-diphosphono-1,2-propanodicarboxylic acid bone scintigraphy performed 315 referred between August 2019 2021. Myocardial tracer uptake...
The 2021 European Society of Cardiology (ESC) screening recommendations for individuals carrying a pathogenic transthyretin amyloidosis variant (ATTRv) are based on expert opinion. We aimed to (i) determine the penetrance ATTRv cardiomyopathy (ATTRv-CM) at baseline; (ii) examine value serial evaluation; and (iii) establish yield first-line diagnostic tests (i.e. electrocardiogram, echocardiogram, laboratory tests) as per ESC position statement.
Tafamidis improves clinical outcomes in transthyretin amyloid cardiomyopathy (ATTR-CM), yet how tafamidis affects cardiac structure and function remains poorly described. This study prospectively analysed the effect of on 12-month longitudinal changes by magnetic resonance (CMR) compared with natural course disease an untreated historic control cohort.
Sex-related differences in prevalence, clinical presentation, and outcome of cardiac channelopathies are increasingly recognized, despite their autosomal transmission hence equal genetic predisposition among sexes. In congenital long-QT syndrome, adult women carry a greater risk for Torsades de pointes sudden death than do men. contrast, Brugada syndrome is observed predominantly men, with considerably higher arrhythmic men women. both conditions, the arrhythmias varies age. Sex-associated...
Even though it has been more than a decade since renal denervation (RDN) was first used to treat hypertension and an intense effort on researching this therapy made, is still not clear how RDN fits into the antihypertensive arsenal. There no question that lowers blood pressure (BP), does so extent at best corresponding one drug. The procedure excellent safety record. However, remains clinically impossible predict whose BP responds not. Long-term efficacy data reduction are unconvincing...
Background Transthyretin amyloid cardiomyopathy (ATTR-CM) often coexists with severe aortic stenosis (AS). Although strain analysis from cardiac MRI and echocardiography was demonstrated to predict coexisting ATTR-CM, comparable data four-dimensional (4D) CT are lacking despite wide availability. Purpose To evaluate the diagnostic performance of 4D CT-derived parameters in identifying ATTR-CM older adults considered for transcatheter valve implantation (TAVI). Materials Methods This...
Quantitative
Our study aimed to determine whether 4D cardiac computed tomography (4DCCT) based quantitative myocardial analysis may improve risk stratification and can predict reverse remodeling (RRM) mortality after transcatheter aortic valve implantation (TAVI).
Background: Despite being the most commonly performed valvular intervention, risk prediction for aortic valve replacement in patients with severe stenosis by currently used scores remains challenging. The study aim was to develop a biomarker-based score means of neuronal network. Methods: In this multicenter study, 3595 were divided into test and validation cohorts (70% 30%) random allocation. Input variables ABC-AS age, cardiac biomarker high-sensitivity troponin T, patient history...
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a frequent concomitant condition in patients with severe aortic stenosis (AS), yet it often remains undetected. This study aims to comprehensively evaluate artificial intelligence-based models developed based on preprocedural and routinely collected data detect ATTR-CM AS planned for transcatheter valve implantation (TAVI).
Abstract Background The 2021 European Society of Cardiology (ESC) screening recommendations for individuals carrying a pathogenic transthyretin amyloidosis (ATTR) variant (ATTRv) are based on expert opinion. We aimed to (1) determine the yield ATTR cardiomyopathy (ATTR-CM) at baseline; (2) evaluate performance ESC position statement initiating ATTRv carriers; (3) establish value first-line tests recommended in and (4) examine serial evaluation. Methods included 159 relatives (median age 55.6...
Systemic amyloidosis is a heterogeneous group of diseases associated with protein misfolding into insoluble beta-sheet rich structures that deposit extracellularly in different organs, eventually compromising their function. There are more than 30 proteins, known to be amyloidogenic “light chain” (AL)-amyloidosis being the most common type, followed by transthyretin (ATTR)-, and amyloid A (AA)-amyloidosis. rare disease an incidence around 10 patients 1 million inhabitants. Recently several...
Microvascular obstruction (MVO) and Late Gadolinium Enhancement (LGE) assessed in cardiac magnetic resonance (CMR) are associated with adverse outcome patients ST-elevation myocardial infarction (STEMI). Our aim was to analyze the diagnostic performance of segmental strain for detection MVO LGE.Patients anterior STEMI, who underwent additional CMR were enrolled this sub-study CARE-AMI trial. Using feature tracking (FT) circumferential peak (SCS) measured SCS discriminate LGE a derivation...
Transthyretin amyloidosis (ATTR amyloidosis) is a disease caused by deposition of transthyretin fibrils in organs and tissues, which causes their dysfunction. The clinical heterogeneity ATTR the variable presentation symptoms at early stages, historically meant treatment delays. Diagnostic tools therapy options have markedly improved recent years. first Swiss Amyloidosis Network (SAN) meeting (Zurich, Switzerland, January 2020) aimed to define consensus statement regarding diagnostic work-up...
Left ventricular remodeling following acute myocardial infarction results in progressive dysfunction and adversely affects prognosis.To investigate the efficacy of paroxetine-mediated G-protein-coupled receptor kinase 2 inhibition to mitigate adverse left patients presenting with infarction.This double-blind, placebo-controlled randomized clinical trial was conducted at Bern University Hospital, Bern, Switzerland. Patients anterior ST-segment elevation ejection fraction (LVEF) 45% or less...
Background: Tafamidis reduces cardiovascular morbidity and mortality in transthyretin amyloid cardiomyopathy (ATTR-CM), yet availability access to therapy vary. Objective: To determine how tafamidis impact time-to-diagnosis, time-to-therapy, outcomes ATTR-CM. Methods Results: 91 consecutive ATTR-CM patients diagnosed between June 2019 2021 were evaluated for tafamidis. Access was regulated by compassionate use [n(CU)=42] prior to, insurance [n(IA)=49] after regulatory approval. started 37/42...